

Glenmark launches fixed-dose combination drug for asthma

20 June 2022 | News

The company has launched it under the brand name Indamet



Mumbai-based Glenmark Pharmaceuticals has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India.

The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily.

While speaking on the development, Alok Malik, Group Vice President & Head, India Formulations – Glenmark Pharmaceuticals said, “Respiratory is a key focus area for Glenmark and the company leads from the front in providing access to the latest treatment options to patients. We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”

Glenmark is the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid which is approved by the DCGI (Drug Controller General of India).

Indamet will help in the management of uncontrolled asthma by improving lung function, better symptom control and reducing exacerbations.